Респираторная медицина. Руководство (в 2-х томах) - Чучалин А. Г. (читать хорошую книгу .txt) 📗
9
СПИСОК ЛИТЕРАТУРЫ
1. Barnes P. Respiratory Pharmacology: General Pharmacologic Principles. Murray & Nadel: Textbook of Respiratory Medicine, 3rd ed., 2000, W. B. Saunders Company, p. 232.
2. Guyton AC. Textbook of medical physiology. Philadelphia, 1986.
3. Johnson M. The beta-adrenoceptor.Am J Respir Crit Care Med. 1998 Nov;158(5 Pt 3):S146-53.
4. Barnes P. Respiratory Pharmacology: General Pharmacologic Principles. Murray & Nadel: Textbook of Respiratory Medicine, 3rd ed., 2000, W. B. Saunders Company, p. 232.
5. Barnes P. Effect of beta agonists on inflammatory cells. J. Allergy Clin. Immunol., 1999, 104 (2), 10-17.
6. McGraw DW, Liggett SB. Molecular mechanisms of beta2-adrenergic receptor function and regulation.Proc Am Thorac Soc. 2005;2(4):292-6;
7. Van Veen A, Weller FR, Wierenga EA et. al. A comparison of salmeterol and formoterol in attenuating airway responses to short-acting beta2-agonists.
8. Tan KS, Grove A, McLean A, Gnosspelius Y, Hall IP, Lipworth BJ. Systemic corticosteriod rapidly reverses bronchodilator subsensitivity induced by formoterol in asthmatic patients. Am J Respir Crit Care Med. 1997 Jul;156(1):28-35.
9. Hanania NA, Sharafkhaneh A, Barber R, Dickey BF. Beta-agonist intrinsic efficacy: measurement and clinical significance. Am J Respir Crit Care Med. 2002 May 15;165(10):1353-8.
10. Scola A-M, Chong LK, Suvarna K. et al. Desensitisation of mast cell b2-adrenoceptor-mediated responses by salmeterol and formoterol. British Journal of Pharmacology (2004) 141, 163 - 171
11. Boonsawat W, et al. Respir Med 2003;97:1067 - 1074
12. Bateman ED, Fairall L, Lombardi DM, English R. Respiratory Research 2006, 7:13
13. Sears MR. The evolution of beta2-agonists. Respir Med. 2001 Aug;95 Suppl B:S2-6.
14. Anderson GP, Linden A, Rabe KF. Why are long-acting beta-adrenoceptor agonists long-acting? Eur Respir J 1994;7:569 - 578.
15. Adkins JC, McTavish D. Salmeterol. A review of its pharmacological properties and clinical efficacy in the management of children with asthma. Drugs. 1997 Aug;54(2):331-54.
16. M. Molimard, E. Naline, Y. Zhang. Long- and short-acting бета2 adrenoceptor agonists: interactions in human contracted bronchi. Eur Respir J 1998; 11: 583 - 588.
17. Hall I.P. бета2-Adrenoceptor Agonists. In Asthma and COPD Basic Mechanisms and Clinical Management, Ed. P. Barnes. 1st ed., 2002, Academic Press.
18. Newman SP, Pavia D, Sheahan NT, et al: Deposition of pressurized aerosols in the lung using radiolabeled particles. Thorax 35:284, 1980.
19. FOWLER SJ, LIPWORTH BJ. Therapeutic equivalence of inhaled salbutamol. Thorax 2000;55:345 - 348.
20. Janson C. Plasma levels and effects of salbutamol after inhaled or i.v. administration in stable asthma. Eur Respir J. 1991 May;4(5):544-50.
21. Lipworth BJ, Clark RA, Fraser CG, et al. The biochemical effects of high-dose inhaled salbutamol in patients with asthma. Eur J Clin Pharmacol 1989;36:357 - 60.
22. Newhouse MT, Chapman KR, McCallum AL, et al. Cardiovascular safety of high doses of inhaled fenoterol and albuterol in acute severe asthma. Chest 1996; 110: 595-603
23. Lipworth BJ. Revisiting interactions between hypoxaemia and beta2-agonists in asthma. Thorax 2001;56:506 - 507
24. Au DH, Lemaitre RN, Curtis JR, Smith NL, Psaty BM. The risk of myocardial infarction associated with inhaled b-adrenoceptor agonists. AM J RESPIR CRIT CARE MED 2000;161:827 - 830.
25. Au DH, Curtis JR, Every NR et al. Association Between Inhaled бета-Agonists and the Risk of Unstable Angina and
26.Myocardial Infarction. CHEST 2002; 121:846 - 851
27. Salpeter SR, Buckley NS, Ormiston TM and Salpeter EE. Meta-Analysis: Effect of Long-Acting бета-Agonists on Severe Asthma Exacerbations and Asthma-Related Deaths. Ann Intern Med. 2006;144:904-912.
28. Nelson HS et al. Pharmacotherapy for Asthma or Usual Pharmacotherapy Plus Salmeterol The Salmeterol Multicenter Asthma Research Trial: A Comparison of Usual Chest 2006;129;15-26
29. Novartis. Drug regulatory affairs: Foradil Aerolizer 12 mcg. http://www.fda.gov/ohrms/dockets/ac/05/briefing/2005-4148B1_02_01-Novartis-Foradil.pdf
30. R.A. Pauwels, M.R. Sears, M. Campbell, C. Villasante, S. Huang, A. Lindh, W. Petermann, M. Aubier, G. Schwabe, T. Bengtsson. Formoterol as relief medication in asthma: a worldwide safety and effectiveness trial. Eur Respir J 2003; 22: 787 - 794.
31. Nemoto T, Ohara-Nemoto Y, Denis M, Gustafsson J-A: The transformed glucocorticoid receptor has a lower steroid-binding affinity than the nontransformed receptor. Biochemistry 1990; 29:1880-1886.
32. Bodine PV, Litwack G: The glucocorticoid receptor and its endogenous regulators. Receptor 1990; 1:83-119.
33. Sher ER, Leung DYM, Surs W, Kam JC, Zeig G, Kamada AK, Harbeck R, Szefler SJ: Steroid resistant asthma: cellular mechanisms contributing to inadequate response to glucocorticoid therapy. J Clin Invest 1994; 93:33-39.
34. Amano Y, Lee SW, Allison AC. Inhibition by glucocorticoids of the formation of interleukin-1 alpha, interleukin-1 beta, and interleukin-6: mediation by decreased mRNA stability. Mol Pharmacol 1993;43:176 - 182
35. Hafezi-Moghadam A, Simoncini T, Yang E, Limbourg FP, Plumier JC, Rebsamen MC, Hsieh CM, Chui DS, Thomas KL, Prorock AJ, et al. Acute cardiovascular protective effects of corticosteroids are mediated by non-transcriptional activation of endothelial nitric oxide synthase. Nat Med 2002;8:473 - 479
36. Orchinik M, Murray TF, Moore FL. A corticosteroid receptor in neuronal membranes. Science 1991;252:1848 - 1851.
37. Stellato C. Post-transcriptional and Nongenomic Effects of Glucocorticoids. The Proceedings of the American Thoracic Society 1:255-263 (2004)
38. Reichardt HM, Kaestner KH, Tuckermann J, et al: DNA binding of the glucocorticoid receptor is not essential for survival. Cell 1998; 93:531-541.
39. Barnes PJ, Adcock IM: Transcription factors and asthma. Eur. Respir. J. 1998; 12:221-234.
40. Peter J. Barnes, K. Fan Chung, and Clive P. Page Inflammatory Mediators of Asthma: An Update Pharmacol. Rev. 1998 50: 515-596.
41. Woolley KL, Gibson PG, Carty K, Wilson AJ, Twaddell SH, Woolley MJ: Eosinophil apoptosis and the resolution of airway inflammation in asthma. Am. J. Respir. Crit. Care Med. 1996; 154:237-243.
42. John M, Lim S, Seybold J, et al: Inhaled corticosteroids increase IL-10 but reduce MIP-1альфа, GM-CSF and IFN-гамма release from alveolar macrophages in asthma. Am. J. Respir. Crit. Care Med. 1998; 157:256-262.
43. Williams CM, Galli SJ: The diverse potential effector and immunoregulatory roles of mast cells in allergic disease. J. Allergy Clin. Immunol. 2000; 105:847-859.
44. Nelson DJ, McWilliam AS, Haining S, Holt PG: Modulation of airway intraepithelial dendritic cells following exposure to steroids. Am. J. Respir. Crit. Care Med. 1995; 151:475-481.
45. Barnes PJ: Mechanism of action of glucocorticoids in asthma. Am. J. Respir. Crit. Care Med. 1996; 154:S21-S27.
46. Kai H, Yoshitake K, Hisatsune A, Kido T, Isohama Y, Takahama K, Miyata T: Dexamethasone suppresses mucus production and MUC-2 and MUC-5AC gene expression by NCI-H292 cells. Am. J. Physiol. 1996; 271:L484-L488.
47. Engel T, Dirksen A, Heinig JH, Nielsen NH, Weeke B, Johansson SA. Single-dose inhaled budesonide in subjects with chronic asthma. Allergy. 1991 Oct;46(7):547-53.
48. Rodrigo GJ. Comparison of inhaled fluticasone with intravenous hydrocortisone in the treatment of adult acute asthma. Am J Respir Crit Care Med. 2005 Jun 1;171(11):1231-6. Epub 2005 Mar 11.
49. Reddel H, Ware S, Marks G, Salome C, Jenkins C, Woolcock A. Differences between asthma exacerbations and poor asthma control. Lancet 1999;353(9150):364-9.
50. Sont JK, Willems LN, Bel EH, van Krieken JH, Vandenbroucke JP, Sterk PJ. Clinical control and histopathologic outcome of asthma when using airway hyperresponsiveness as an additional guide to long-term treatment. The AMPUL Study Group. Am J Respir Crit Care Med 1999;159(4 Pt 1):1043-51.
